A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
Clinical trial NCT05172856 · UNKNOWN
Trial details
- NCT number
- NCT05172856
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-01
- Primary completion
- 2023-06-30
- Enrollment
- 110
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.